Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).

被引：0
|
作者：
Grivas, Petros
Agarwal, Neeraj
Siefker-Radtke, Arlene O.
Daignault, Stephanie
Puzanov, Igor
MacVicar, Gary R.
Levine, Ellis Glenn
Srinivas, Sandy
Twardowski, Przemyslaw
Eisenberger, Mario A.
Quinn, David I.
Vaishampayan, Ulka N.
Yu, Evan Y.
Dawsey, Scott
Day, Kathleen C.
Day, Mark L.
Smith, David C.
Hussain, Maha
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Northwestern Univ, Feinberg Sch Med, Div Hematol & Med Oncol, Chicago, IL 60611 USA
[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[7] Stanford Med Ctr, Stanford, CA USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[11] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[13] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
    Hussain, Maha
    Daignault, Stephanie
    Agarwal, Neeraj
    Grivas, Petros D.
    Siefker-Radtke, Arlene O.
    Puzanov, Igor
    MacVicar, Gary R.
    Levine, Ellis Glenn
    Srinivas, Sandy
    Twardowski, Przemyslaw
    Eisenberger, Mario A.
    Quinn, David I.
    Vaishampayan, Ulka N.
    Yu, Evan Y.
    Dawsey, Scott
    Day, Kathleen C.
    Day, Mark L.
    Al-Hawary, Mahmoud
    Smith, David C.
    [J]. CANCER, 2014, 120 (17) : 2684 - 2693
  • [2] Phase II study of gemcitabine, cisplatin and sunitinib in patients with advanced urothelial carcinoma (UC).
    Galsky, M. B.
    Sonpavde, G.
    Hellerstedt, B. A.
    McKenney, S. A.
    Hutson, T. E.
    Rauch, M. A.
    Wang, Y.
    Boehm, K. A.
    Asmar, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC)
    Galsky, Matt D.
    Hellerstedt, Beth A.
    O'Rourke, Mark Allen
    Vogelzang, Nicholas J.
    Kocs, Darren M.
    McKenney, Scott A.
    Melnyk, Anton M.
    Hutson, Thomas E.
    Rauch, Mary Ann
    Wang, Yunfei
    Asmar, Lina
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma A Phase 2 Randomized Clinical Trial
    Pal, Sumanta K.
    Frankel, Paul H.
    Mortazavi, Amir
    Milowsky, Matthew
    Vaishampayan, Ulka
    Parikh, Mamta
    Lyou, Yung
    Weng, Peng
    Parikh, Rahul
    Teply, Benjamin
    Dreicer, Robert
    Emamekhoo, Hamid
    Michaelson, Dror
    Hoimes, Christopher
    Zhang, Tian
    Srinivas, Sandy
    Kim, William Y.
    Cui, Yujie
    Newman, Edward
    Lara, Primo N., Jr.
    [J]. JAMA ONCOLOGY, 2021, 7 (10) : 1536 - 1543
  • [6] Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC)
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
    Pal, Sumanta K.
    Mortazavi, Amir
    Milowsky, Matthew I.
    Vaishampayan, Ulka N.
    Parikh, Mamta
    Lyou, Yung
    Wang, Peng
    Parikh, Rahul Atul
    Teply, Benjamin A.
    Dreicer, Robert
    Emamekhoo, Hamid
    Michaelson, M. Dror
    Hoimes, Christopher J.
    Zhang, Tian
    Srinivas, Sandy
    Kim, William Y.
    Liu, Glenn
    Frankel, Paul Henry
    Cui, Yuijie
    Lara, Primo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab
    Alva, A. S.
    Agarwal, N.
    Slefker-Radtke, A. O.
    Roth, B. J.
    Smith, D. C.
    Dalgnault, S.
    Srinivas, S.
    Bradley, D. A.
    Hussain, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
    Wong, Yu-Ning
    Litwin, Samuel
    Vaughn, David
    Cohen, Seth
    Plimack, Elizabeth R.
    Lee, James
    Song, Wei
    Dabrow, Michael
    Brody, Marion
    Tuttle, Holly
    Hudes, Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3545 - 3551
  • [10] Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): A randomized placebo controlled phase II trial
    Bradley, D.
    Daignault, S.
    Smith, D. C.
    Nanus, D.
    Tagawa, S.
    Stadler, W. M.
    Garcia, J.
    Dreicer, R.
    Al-Hawary, M.
    Hussain, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345